CERN Investigators Publish Paper on Phase II Study

— Categories: CERN Research Articles     Posted on May 14, 2015

In an open-label, two-stage, phase II study (CERN 08-01), CERN investigators aim to investigate the effect of bevacizumab and lapatinib in children with recurrent or refractory ependymoma.

Although the combination of bevacizumab and lapatinib was well tolerated in children with recurrent ependymoma, it proved ineffective.

To read the PubMed Abstract, click here.

Stay Informed with the CERN Newsletter

The CERN Foundation is committed to informing you with the latest ependymoma news and research. Join our mailing list for monthly updates.